Skip to main content
Figure 4 | Molecular Pain

Figure 4

From: ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response

Figure 4

Effect of ARA 290 on Iba-1 immunoreactivity on L1-L6 spinal cord segments of animals 2 and 20 weeks after spared nerve injury. A. Representative photomicrographs of Iba-1 immunoreactivity (green) in the lumbar dorsal horns of animals 2 weeks after spared nerve injury (SNI). Animals were either treated with vehicle (upper row), 10 μg/kg ARA 290 (second row) or 30 μg/kg ARA 290 (third row). The bottom row represents sham-operated animals without treatment. In each column, the Iba-1 immunoreactivity signal at different lumbar spinal cord levels (L1-L6) is shown. Inserts show higher magnifications of the photomicrographs. B. Representative photomicrographs of Iba-1 immunoreactivity (green) in the lumbar dorsal horns of animals 20 weeks after spared nerve injury (SNI). Animals were either treated with vehicle (upper row), 10 μg/kg ARA 290 (second row) or 30 μg/kg ARA 290 (third row). The bottom row represents sham-operated animals without treatment. In each column, the Iba-1 immunoreactivity signal at different lumbar spinal cord levels (L1-L6) is shown. Inserts show higher magnifications of the photomicrographs.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us